Chester County News and Community Website
MALVERN, PA — YPrime recently launched a new Participant Hub within its electronic clinical outcome assessment platform aimed at improving patient engagement and retention in clinical trials.
YPrime Launches eCOA Participant Hub to Improve Trial Engagement Read More
WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) has enrolled the first patient in its Phase 3 clinical trial evaluating IKT-001 for pulmonary arterial hypertension, advancing development of the drug …
Inhibikase Enrolls First Patient in Phase 3 PAH Trial Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) recently submitted an updated Phase 2 clinical study design to the U.S. Food and Drug Administration for Teverelix, an investigational treatment aimed …
Medicus Submits Phase 2 Study Design for Teverelix to FDA Read More
WILMINGTON, DE — AstraZeneca reported that its drug combination including IMFINZI and IMJUDO, used with lenvatinib and transarterial chemoembolization, improved progression-free survival in patients with unresectable liver cancer eligible for …
AstraZeneca Trial Shows Improved Outcomes in Liver Cancer Study Read More
PHILADELPHIA, PA — The U.S. Food and Drug Administration recently granted Breakthrough Therapy Designation to plixorafenib, an investigational drug from FORE Biotherapeutics, for the treatment of adults with BRAF V600E-mutated …
FDA Grants Breakthrough Status to Fore Bio Brain Cancer Drug Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) issued a clarification of previously reported Phase 2 trial results for its SkinJect therapy in nodular basal cell carcinoma, the company said.
Medicus Clarifies Phase 2 Results for SkinJect Cancer Therapy Read More
MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has completed enrollment and dosing in its Phase 2/3 clinical trial evaluating a gene therapy candidate for Stargardt disease.
Ocugen Completes Dosing in Stargardt Disease Gene Therapy Trial Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced the publication of an article detailing the development of its lead drug candidate buntanetap as the company continues clinical trials for …
Annovis Bio Highlights Buntanetap Development in Published Article Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported a confirmed partial response in its ongoing Phase 1 clinical trial evaluating APR-1051, a WEE1 kinase inhibitor, in patients with biomarker-defined …
Aprea Reports Partial Response in APR-1051 Cancer Trial Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it has submitted an optimized Phase 2 clinical trial protocol to the U.S. Food and Drug Administration for teverelix, an investigational …
Medicus Pharma Submits Phase 2 Protocol for Teverelix to FDA Read More